Venture-capital funding in the United Kingdom represents a boost for translational research.
A £250-million (US$397-million) investment in venture capital for translational research in the United Kingdom could create jobs. The European Investment Fund in Luxembourg City and Cancer Research Technology (CRT), the commercial arm of the London-based charity Cancer Research UK, are jointly investing £50 million in the development of potential cancer drugs. A separate £200-million initiative by the Wellcome Trust in London will support early-stage biotechnology firms. Keith Blundy, chief executive of CRT, says that experts in drug development should find opportunities as the funding helps to take more drug candidates through to clinical trials.
Related links
Related links
Related links in Nature Research
Wellcome Trust launches venture-capital business : News blog
Start-ups: In search of venture capital
Related external links
Rights and permissions
About this article
Cite this article
UK drug development. Nature 484, 407 (2012). https://doi.org/10.1038/nj7394-407d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7394-407d